Since SRC-3 deficiency prevents atherosclerosis development, we assessed the protective effect of bufalin, a small-molecule inhibitor of SRC-3 that has been used in tumor therapy 28, 29, in the development of atherosclerosis. Here, NCOA3 is linked to neoplasm.